Harvard Bioscience (HBIO) Common Equity (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Common Equity data on file, last reported at $10.0 million in Q1 2026.

• Quarterly Common Equity fell 32.28% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (down 32.28% YoY) and the FY2025 annual result came in at $13.7 million, down 78.32% from the prior year.
• Common Equity declined to $10.0 million in Q1 2026 per HBIO's latest filing, from $13.7 million in the prior quarter.
• Across five years, Common Equity topped out at $77.5 million in Q2 2022 and bottomed at $10.0 million in Q1 2026.
• The 5-year median for Common Equity is $68.8 million (2024), against an average of $54.6 million.
• The widest annual swing landed in 2023, when Common Equity gained 3.21%; it then plunged 78.46% in 2025.
• Tracing HBIO's Common Equity over 5 years: stood at $72.2 million in 2022, then rose by 1.18% to $73.1 million in 2023, then retreated by 13.32% to $63.3 million in 2024, then tumbled by 78.32% to $13.7 million in 2025, then retreated by 26.85% to $10.0 million in 2026.
• Per Business Quant, the three latest HBIO Common Equity figures stand at $10.0 million (Q1 2026), $13.7 million (Q4 2025), and $14.1 million (Q3 2025).

Peer Comparison